Antibodies against nuclear components (ANAs) occur in sera of approximately 50% of patients with primary biliary cirrhosis (PBC). By indirect immunofluorescence (IIF) ANA-positive PBC sera generate most frequently, homogeneous, speckled, centromere, and rim-like staining patterns. A perinuclear staining pattern is indicative for the reactivity of the sera with the components of the nuclear envelope. A substantial subset of PBC patients develops antibodies against constituents of the nuclear pore complexes (NPCs). These autoantibodies target two major autoantigens: gp210 glycoprotein and p62 kDa nucleoporin. Originally, a strong reaction of PBC with a 60 kDa protein of NPCs that was affinity purified on wheat-germ agglutinin (WGA)-Sepharose was described. Recently, using human recombinant p62 nucleoporin the identity of the reactivity was confirmed. In this work we compared by immunoprecipitation the reactivity of 20 PBC sera with the two recombinant autoantigens of the NPCs. Two out of 20 (10%) PBC sera precipitated recombinant gp210 glycoprotein and 11 out of 20 (55%) PBC sera reacted with p62 nucleoporin. These results evidence that anti-p62 antibodies occur more frequently than the autoantibodies against gp210 glycoprotein. Considering the recently reported clinical significance of ANAs in PBC, the prognostic value of the anti-NPC antibodies and their correlation with severity and progression of the disease is under evaluation.

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1398.058DOI Listing

Publication Analysis

Top Keywords

pbc sera
16
gp210 glycoprotein
12
components nuclear
8
nuclear pore
8
pore complexes
8
pbc
8
p62 nucleoporin
8
sera
6
antibodies
5
characterization autoantibodies
4

Similar Publications

Obeticholic Acid Aggravates Liver Fibrosis by Activating Hepatic Farnesoid X Receptor-induced Apoptosis in Cholestatic Mice.

Chem Biol Interact

December 2024

New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China. Electronic address:

Obeticholic acid (OCA) was approved for the treatment of primary biliary cholangitis (PBC) patients. However, it can cause severe drug-induced liver injury (DILI), which may put PBC patients at risk of acute-on-chronic liver failure (ACLF) and even death. Farnesoid X receptor (FXR) is considered as the target of OCA for cholestasis, but there is still a lack of research on whether hepatic and ileal FXR have different effects after OCA treatment.

View Article and Find Full Text PDF

Primary Biliary Cholangitis: personalizing second-line therapies.

Hepatology

November 2024

Department of Medicine, Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California, USA.

Article Synopsis
  • Primary biliary cholangitis (PBC) is an autoimmune disease primarily affecting middle-aged women, characterized by damage to small bile ducts, leading to liver issues like cholestasis and cirrhosis.
  • The main treatment for PBC has been ursodeoxycholic acid, which helps slow disease progression but doesn't alleviate symptoms; new second-line therapies are being developed for patients who don't respond well.
  • Recent medications like obeticholic acid, elafibranor, and seladelpar show promise in improving liver function and reducing cholestasis, while considerations for personalized treatment based on patient features are essential.
View Article and Find Full Text PDF
Article Synopsis
  • * AIH frequently occurs alongside other autoimmune diseases, complicating diagnosis and treatment due to the lack of standardized protocols and the rarity of the condition, which limits research and treatment options.
  • * A case study highlights a 54-year-old woman with acute hepatitis that escalated to liver failure; upon diagnosis of AIH and primary biliary cholangitis (PBC), she was treated with corticosteroids, demonstrating the complexities of overlap syndromes.
View Article and Find Full Text PDF

Background & Aims: Biliary epithelial senescence is involved in the pathogenesis of primary biliary cholangitis (PBC). We hypothesized that a unique subtype of programmed death-ligand 1 (PD-L1)-positive senescent biliary epithelial cells (BECs) may be related to the pathogenesis of PBC in association with cyclic GMP-AMP synthase (cGAS)- stimulator of interferon genes (STING) pathway.

Approach & Results: The expression of PD-L1, STING and their association with senescent markers p16 and p21 were immunohistochemically determined in livers taken from the patients with PBC (n = 87) and 97 diseased and normal control livers.

View Article and Find Full Text PDF
Article Synopsis
  • * A new monoclonal chimeric IgG1 antibody, called 4G6, has been developed from a murine-specific antibody for the inner lipoyl domain of PDC-E2 and can recognize all AMA epitopes used in current diagnostic tests.
  • * The 4G6 antibody demonstrates strong binding affinity, making it a reliable quantitative reference for AMA testing and a promising standard for international use.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!